Axatilimab effective, safe for chronic graft-versus-host disease

SALT LAKE CITY — Axatilimab appeared effective for heavily pretreated patients with active chronic graft-versus-host disease, according to phase 1/phase 2 study results.
More than two-thirds of patients treated at two doses selected for further investigation responded to therapy, and more than half of patients reported clinically meaningful improvement in symptoms.
The agent also appeared safe, findings presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR showed.
An estimated 30% to 50% of allogeneic hematopoietic stem cell transplant

SALT LAKE CITY — Axatilimab appeared effective for heavily pretreated patients with active chronic graft-versus-host disease, according to phase 1/phase 2 study results.
More than two-thirds of patients treated at two doses selected for further investigation responded to therapy, and more than half of patients reported clinically meaningful improvement in symptoms.
The agent also appeared safe, findings presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR showed.
An estimated 30% to 50% of allogeneic hematopoietic stem cell transplant